

Title (en)
Novel isatinoxime derivatives, their preparation and use.

Title (de)
Isatinoximderivate, ihre Herstellung und Anwendung.

Title (fr)
Dérivés d'isatinoxime, leur préparation et utilisation.

Publication
EP 0529636 A1 19930303 (EN)

Application
EP 92114654 A 19920827

Priority
• US 75116591 A 19910828
• US 83185192 A 19920205

Abstract (en)
A compound having the formula <CHEM> wherein R<4> and R<5> independently are hydrogen, halogen, CF₃, CN, NO₂ or SO₂NR<1>R<2> wherein R<1> is hydrogen or straight, C1-6-alkyl which may be branched or cyclic, R<2> is hydrogen or straight, C1-6-alkyl which may be branched or cyclic, or wherein R<1> and R<2> together represent -(CH₂)_n-A-(CH₂)_m-, wherein A is O, S, CH₂ or NR<I>-, wherein R<I> is H, C1-6-alkyl which may be straight, branched or cyclic, n is 0, 1, 2, 3, 4, 5 and m is 0, 1, 2, 3, 4, 5; Q is NOH, O; Z = O, S, N-R<II>-, <CHEM> wherein R<II>, R<III>, R<IV> and R<V> independently are hydrogen, benzyl, C1-6-acyl, C1-6-alkoxy which may be branched or cyclic, or C1-6-alkyl which may be branched or cyclic; X is -(CH₂)_o- wherein o is 0, 1, 2, or 3; Y is -(CH₂)_p- wherein p is 0, 1, 2 or 3; alpha and beta indicate attachment points, and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.

IPC 1-7
A61K 31/40; A61K 31/435; A61K 31/55; C07D 471/04; C07D 487/04; C07D 491/048; C07D 495/04

IPC 8 full level
A61K 31/40 (2006.01); **A61K 31/404** (2006.01); **A61K 31/407** (2006.01); **A61K 31/435** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4738** (2006.01); **A61K 31/55** (2006.01); **A61P 25/00** (2006.01); **A61P 25/06** (2006.01); **A61P 25/18** (2006.01); **A61P 25/28** (2006.01); **C07C 205/45** (2006.01); **C07D 209/12** (2006.01); **C07D 209/90** (2006.01); **C07D 209/94** (2006.01); **C07D 471/04** (2006.01); **C07D 487/04** (2006.01); **C07D 491/04** (2006.01); **C07D 491/044** (2006.01); **C07D 491/048** (2006.01); **C07D 495/04** (2006.01)

CPC (source: EP)
A61P 25/00 (2017.12); **A61P 25/06** (2017.12); **A61P 25/18** (2017.12); **A61P 25/28** (2017.12); **C07C 205/45** (2013.01); **C07D 471/04** (2013.01); **C07D 487/04** (2013.01); **C07D 491/04** (2013.01); **C07D 495/04** (2013.01)

Citation (search report)
[AD] EP 0432648 B1 19950802 - NEUROSEARCH AS [DK]

Cited by
EP0633262A1; US5780493A; US5843945A; AU686888B2; US5801174A; EP0904777A1; FR2768624A1; CN104995171A; EA027009B1; CN108912127A; US5917053A; CN108777958A; US6124285A; USRE38200E; CZ297938B6; WO9426747A1; WO2014095675A1; WO9608495A1; WO9608494A1; US6703391B2; US9376391B2; US7601360B2; US6616933B1; US6693111B1; US7595336B2; US7282511B2; TWI669290B; US11208374B2; US11319277B2; EP0869958B1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
EP 0529636 A1 19930303; EP 0529636 B1 19990623; AT E181552 T1 19990715; AU 2482092 A 19930405; AU 655672 B2 19950105; CA 2076948 A1 19930301; CA 2076948 C 20020416; CZ 282759 B6 19970917; CZ 39594 A3 19941116; DE 69229461 D1 19990729; DE 69229461 T2 19991021; DK 0529636 T3 19991213; FI 107156 B 20010615; FI 940889 A0 19940225; FI 940889 A 19940225; GE P20002329 B 20001225; HU 211632 A9 19951228; HU 9400595 D0 19940530; HU T70753 A 19951030; JP 3170584 B2 20010528; JP H06510056 A 19941110; KR 100277481 B1 20010201; MX 9204914 A 19930701; NO 301117 B1 19970915; NO 940676 D0 19940225; NO 940676 L 19940427; PL 170920 B1 19970228; RU 2114827 C1 19980710; SK 23894 A3 19941207; SK 280578 B6 20000410; WO 9305043 A1 19930318

DOCDB simple family (application)
EP 92114654 A 19920827; AT 92114654 T 19920827; AU 2482092 A 19920827; CA 2076948 A 19920826; CZ 39594 A 19920827; DE 69229461 T 19920827; DK 92114654 T 19920827; EP 9201999 W 19920827; FI 940889 A 19940225; GE AP1992002683 A 19920827; HU 9400595 A 19920827; HU 9500323 P 19950621; JP 50493393 A 19920827; KR 19940700676 A 19940228; MX 9204914 A 19920826; NO 940676 A 19940225; PL 30258492 A 19920827; RU 94019425 A 19920827; SK 23894 A 19920827